Natural self-assembly of Allergen-S-Layer fusion proteins is no prerequisite for reduced allergenicity and T cell stimulatory capacity

International Archives of Allergy and Immunology

Volumn 149, Issue 3, 2009, Pages 231-238

  Gerstmayr, Marianne ^a   Ilk, Nicola ^c   Jahn Schmid, Beatrice ^a   Sleytr, Uwe B ^c   Bohle, Barbara ^a,b  

^a Department of Pathophysiology ^*  (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

Allergy; Antigen presentation; Major birch pollen allergen; Recombinant fusion protein; Specific immunotherapy; Vaccines

Indexed keywords

BACTERIAL PROTEIN; CALCIUM ION; EPITOPE; HYBRID PROTEIN; IMMUNOGLOBULIN E; POLLEN ANTIGEN; PROTEIN BET V 1; PROTEIN SBPA; UNCLASSIFIED DRUG; ALLERGEN; BET V 1 ALLERGEN, BETULA VERRUCOSA; GLUCOSE TRANSPORTER; PLANT ANTIGEN; SBPA PROTEIN, BACTERIA;

ALLERGENICITY; ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; BASOPHIL; BIRCH; CARBOXY TERMINAL SEQUENCE; CELL ACTIVATION; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; RHINOCONJUNCTIVITIS; T LYMPHOCYTE; BLOOD; CELL LINE; DRUG EFFECT; HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; POLLEN;

ALLERGENS; ANTIGEN-PRESENTING CELLS; ANTIGENS, PLANT; BACTERIAL PROTEINS; BETULA; CELL LINE; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; LYMPHOCYTE ACTIVATION; MONOSACCHARIDE TRANSPORT PROTEINS; POLLEN; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 59849090766     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000199718     Document Type: Article

References (38)

1. Bellinghausen I, Metz G, Enk AH, Christ- mann S, Knop J, Saloga J: Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997;27:1131-1139.
2. Jutel M, Akdis M, Budak F, Aebischer-Casa- ulta C, Wrzyszcz M, Blaser K, Akdis CA: IL- 10 and TGF-ß cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:1205-1214.
3. Bousquet J, Lockey R, Malling H: World Health Organization Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy 1998;53:20-22.
4. Wohrl S, Gamper S, Hemmer W, Heinze G, Stingl G, Kinaciyan T: Premedication with montelukast reduces local reactions of allergen immunotherapy. Int Arch Allergy Immunol 2007;144:137-142.
5. Valenta R, Niederberger V: Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007;119:826-830.
6. Vrtala S, Hirtenlehner K, Vangelista L, Pas-tore A, Eichler HG, Sperr WR, Valent P, Eb-ner C, Kraft D, Valenta R: Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997; 99:1673-1681.
7. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, Reisinger J, Pelz-mann M, Hayek B, Kronqvist M, Gafvelin G, Gronlund H, Purohit A, Suck R, Fiebig H, Cromwell O, Pauli G, van Hage-Hamsten M, Valenta R: Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004;101(suppl 2):14677-14682.
8. Kahlert H, Suck R, Weber B, Nandy A, Wald M, Keller W, Cromwell O, Fiebig H: Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen- specific immunotherapy. Int Arch Allergy Immunol 2008; 145: 193-206.
9. Vrtala S, Hirtenlehner K, Susani M, Akdis M, Kussebi F, Akdis CA, Blaser K, Hufnagl P, Binder BR, Politou A, Pastore A, Vangelista L, Sperr WR, Semper H, Valent P, Ebner C, Kraft D, Valenta R: Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 2001; 15:2045-2047.
10. Kussebi F, Karamloo F, Rhyner C, Schmid- Grendelmeier P, Salagianni M, Mannhart C, Akdis M, Soldatova L, Markovic-Housley Z, Von Beust BR, Kundig T, Kemeny DM, Bla-ser K, Crameri R, Akdis CA: A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J Allergy Clin Immunol 2005;115:323-329.
11. Linhart B, Hartl A, Jahn-Schmid B, Verdino P, Keller W, Krauth MT, Valent P, Horak F, Wiedermann U, Thalhamer J, Ebner C, Kraft D, Valenta R: A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J Allergy Clin Immunol 2005;115:1010-1016.
12. Hufnagl K, Winkler B, Focke M, Valenta R,
13. Scheiner O, Renz H, Wiedermann U: Intra- nasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensiti- zation in mice. J Allergy Clin Immunol 2005;
14. 116: 370-376.
15. Bonura A, Corinti S, Artale A, Di Felice G, Amoroso S, Melis M, Geraci D, Colombo P: A hybrid expressing genetically engineered major allergens of the Parietaria pollen as a tool for specific allergy vaccination. Int Arch Allergy Immunol 2007; 142:274-284.
16. Lund L, Henmar H, Wurtzen PA, Lund G, Hjortskov N, Larsen JN: Comparison of al- lergenicity and immunogenicity of an intact allergen vaccine and commercially available allergoid products for birch pollen immunotherapy. Clin Exp Allergy 2007;37:564-571.
17. Maecker HT, Hansen G, Walter DM, DeKruyff RH, Levy S, Umetsu DT: Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. J Immunol 2001; 166: 959-965.
18. Bublin M, Hoflehner E, Wagner B, Radauer C, Wagner S, Hufnagl K, Allwardt D, Kundi M, Scheiner O, Wiedermann U, Breiteneder H: Use of a genetic cholera toxin B subunit/ allergen fusion molecule as mucosal delivery system with immunosuppressive activity against Th2 immune responses. Vaccine 2007;25: 8395-8404.
19. Breitwieser A, Egelseer EM, Moll D, Ilk N, Hotzy C, Bohle B, Ebner C, Sleytr UB, Sara M: A recombinant bacterial cell surface (S- layer)-major birch pollen allergen-fusion protein (rSbsC/Bet v1) maintains the ability to self-assemble into regularly structured monomolecular lattices and the functionality of the allergen. Protein Eng 2002; 15:243-249.
20. Bohle B, Breitwieser A, Zwolfer B, Jahn-Schmid B, Sara M, Sleytr UB, Ebner C: A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immu- nomodulating capacity. J Immunol 2004; 172: 6642-6648.
21. Gerstmayr M, Ilk N, Schabussova I, Jahn- Schmid B, Egelseer EM, Sleytr UB, Ebner C, Bohle B: A novel approach to specific allergy treatment: the recombinant allergen-S-layer fusion protein rSbsC-Bet v 1 matures dendritic cells that prime Th0/Th1 and IL-10- producing regulatory T cells. J Immunol 2007;179: 7270-7275.
22. Sleytr UB, Huber C, Ilk N, Pum D, Schuster B, Egelseer EM: S-layers as a tool kit for nanobiotechnological applications. FEMS Microbiol Lett 2007; 267:131-144.
23. Ilk N, Kosma P, Puchberger M, Egelseer EM, Mayer HF, Sleytr UB, Sara M: Structural and functional analyses of the secondary cell wall polymer of Bacillus sphaericus CCM 2177 that serves as an S-layer-specific anchor. J Bacteriol 1999;181:7643-7646.
24. Ilk N, Vollenkle C, Egelseer EM, Breitwieser A, Sleytr UB, Sara M: Molecular characterization of the S-layer gene, sbpA, of Bacillus sphaericus CCM 2177 and production of a functional S-layer fusion protein with the ability to recrystallize in a defined orientation while presenting the fused allergen. Appl Environ Microbiol 2002;68:3251-3260.
25. SchimekEM, ZwolferB, BrizaP, Jahn-Schmid B, Vogel L, Vieths S, Ebner C, Bohle B: Gastrointestinal digestion of Bet v 1-homologous food allergens destroys their mediator-releasing, but not T cell-activating, capacity. J Allergy Clin Immunol 2005; 116:1327-1333.
26. Vogel L, Luttkopf D, Hatahet L, Haustein D, Vieths S: Development of a functional in vitro assay as a novel tool for the standardization of allergen extracts in the human system. Allergy 2005;60:1021-1028.
27. Jahn-Schmid B, Radakovics A, Lüttkopf D, Scheurer S, Vieths S, Ebner C, Bohle B: Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens. J Allergy Clin Immunol 2005; 116: 213-219.
28. Kahlert H, Grage-Griebenow E, Stuwe HT, Cromwell O, Fiebig H: T cell reactivity with allergoids: influence of the type of APC. J Immunol 2000;165:1807-1815.
29. Ebner C, Schenk S, Najafian N, Siemann U, Steiner R, Fischer GW, Hoffmann K, Szepfa- lusi Z, Scheiner O, Kraft D: Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients. J Immunol 1995; 154:1932-1940.
30. Fritsch R, Bohle B, Vollmann U, Wieder-mann U, Jahn-Schmid B, Krebitz M, Breit- eneder H, Kraft D, Ebner C: Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cells. J Allergy Clin Immunol 1998; 102: 679-686.
31. Jahn-Schmid B, Graninger M, Glozik M, Kupcu S, Ebner C, Unger FM, Sleytr UB, Messner P: Immunoreactivity of allergen (Bet v 1) conjugated to crystalline bacterial cell surface layers (S-layers). Immunotech-nology 1996; 2:103-113.
32. Jahn-Schmid B, Siemann U, Zenker A, Boh- le B, Messner P, Unger FM, Sleytr UB, Schei- ner O, Kraft D, Ebner C: Bet v 1, the major birch pollen allergen, conjugated to crystalline bacterial cell surface proteins, expands allergen-specific T cells of the Th1/Th0 phe- notype in vitro by induction of IL-12. Int Immunol 1997;9:1867-1874.
33. Akdis CA, Blesken T, Wymann D, Akdis M, Blaser K: Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur J Immunol 1998; 28:914-925.
34. Santamaria LF, Bheekha R, van Reijsen FC, Perez Soler MT, Suter M, Bruijnzeel-Koomen CA, Mudde GC: Antigen focusing by specific monomeric immunoglobulin E bound to CD23 on Epstein-Barr virus-transformed B cells. Hum Immunol 1993;37:23-30.
35. van Neerven RJ, Knol EF, Ejrnaes A, Wurt- zen PA: IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy. Int Arch Allergy Immunol 2006; 141: 119-129.
36. Savina A, Amigorena S: Phagocytosis and antigen presentation in dendritic cells. Immunol Rev 2007;219:143-156.
37. Rabinovitch M, De Stefano MJ: Particle recognition by cultivated macrophages. J Immunol 1973; 110: 695-701.
38. Cella M, Sallusto F, Lanzavecchia A: Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9:10-16.